Business Description
Giant Biogene Holding Co Ltd
ISIN : KYG3887G1091
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1384.64 | |||||
Equity-to-Asset | 0.88 | |||||
Interest Coverage | 14926.26 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 47.13 | |||||
Beneish M-Score | -2.74 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 40.2 | |||||
3-Year EBITDA Growth Rate | 25.7 | |||||
3-Year EPS without NRI Growth Rate | 24.3 | |||||
3-Year FCF Growth Rate | 20.3 | |||||
3-Year Book Growth Rate | 107 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.97 | |||||
9-Day RSI | 67.22 | |||||
14-Day RSI | 67.2 | |||||
6-1 Month Momentum % | 30.7 | |||||
12-1 Month Momentum % | 23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.79 | |||||
Quick Ratio | 7.42 | |||||
Cash Ratio | 7.12 | |||||
Days Inventory | 121.18 | |||||
Days Sales Outstanding | 7.9 | |||||
Days Payable | 55.31 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward Dividend Yield % | 0.99 | |||||
3-Year Average Share Buyback Ratio | 0.3 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 83.63 | |||||
Operating Margin % | 47.24 | |||||
Net Margin % | 41.19 | |||||
FCF Margin % | 40.27 | |||||
ROE % | 40.45 | |||||
ROA % | 36.13 | |||||
ROIC % | 175.56 | |||||
ROC (Joel Greenblatt) % | 256.51 | |||||
ROCE % | 48.03 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 30.17 | |||||
PE Ratio without NRI | 30.68 | |||||
Price-to-Owner-Earnings | 29.23 | |||||
PS Ratio | 12.42 | |||||
PB Ratio | 10.05 | |||||
Price-to-Tangible-Book | 10.01 | |||||
Price-to-Free-Cash-Flow | 30.7 | |||||
Price-to-Operating-Cash-Flow | 26.52 | |||||
EV-to-EBIT | 22.52 | |||||
EV-to-EBITDA | 22.09 | |||||
EV-to-Revenue | 11.15 | |||||
EV-to-FCF | 27.7 | |||||
Price-to-Graham-Number | 3.68 | |||||
Price-to-Net-Current-Asset-Value | 12.35 | |||||
Price-to-Net-Cash | 13.75 | |||||
Earnings Yield (Greenblatt) % | 4.44 | |||||
FCF Yield % | 3.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Giant Biogene Holding Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | 3,854.636 | ||
EPS (TTM) (HK$) | 1.619 | ||
Beta | 0 | ||
Volatility % | 36.04 | ||
14-Day RSI | 67.2 | ||
14-Day ATR (HK$) | 1.791212 | ||
20-Day SMA (HK$) | 45.5225 | ||
12-1 Month Momentum % | 23 | ||
52-Week Range (HK$) | 28.4 - 49.15 | ||
Shares Outstanding (Mil) | 981.64 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Giant Biogene Holding Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Giant Biogene Holding Co Ltd Stock Events
Event | Date | Price(HK$) | ||
---|---|---|---|---|
No Event Data |
Giant Biogene Holding Co Ltd Frequently Asked Questions
What is Giant Biogene Holding Co Ltd(HKSE:02367)'s stock price today?
When is next earnings date of Giant Biogene Holding Co Ltd(HKSE:02367)?
Does Giant Biogene Holding Co Ltd(HKSE:02367) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |